TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01258634

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Study: NCT04649840

Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral and cellular immunity
Description: Humoral (IgG) and cellular (antigen-specific cells) immunity

Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral and cellular immunity
Description: Humoral (IgG) and cellular (antigen-specific cells) immunity
Study: NCT02049905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Study: NCT04441528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lid wipes containing terpinen-4-ol and sodium hyaluronate
Description: Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study: NCT00044629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate (Ambien)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02549287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: An evidence-based home visiting program
Study: NCT01258634

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Description: Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
Study: NCT03819140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
Study: NCT00689026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol with electrolytes
Description: Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol with electrolytes
Description: Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
Study: NCT01552954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education of low salt diet
Description: For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
Study: NCT01383265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water method and chromoendoscopy
Description: Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water method
Description: Control method will use plain water with water method for screening colonoscopy
Study: NCT04000009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
Study: NCT01579409

Intervention type: OTHER
Group type: OTHER
Intervention: PNNS guidelines
Description: Application of PNNS guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: PNNS guidelines
Description: Application of PNNS guidelines
Study: NCT03654209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: APC will be applied to the perimeter of the resection site

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation
Description: STSC will be applied to the perimeter of the resection site
Study: NCT02062047

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMSRP
Description: FMSRP in a maximum of 24 hours.
Study: NCT02701712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance - guided radiation therapy (MRgRT)
Description: Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
Study: NCT01235403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks
Study: NCT03258749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhaled Tiotropium(18μg, qd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: inhaled formoterol(4.5μg, bid)
Study: NCT02175355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Micardis®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of Micardis®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Micardis®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04173455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZ-A-018
Description: In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort.
Study: NCT01089231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corn oil)
Description: corn oil (6 capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corn oil)
Description: corn oil (6 capsules per day)
Study: NCT04838990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDSS
Description: Neurological Exam - EDSS (Expanded Disability Status Scale)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDSS
Description: Neurological Exam - EDSS (Expanded Disability Status Scale)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDSS
Description: Neurological Exam - EDSS (Expanded Disability Status Scale)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discussion of symptoms, Patient reported outcome (MSIS)
Description: Patients will be asked about their wellbeing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion of symptoms, Patient reported outcome (MSIS)
Description: Patients will be asked about their wellbeing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion of symptoms, Patient reported outcome (MSIS)
Description: Patients will be asked about their wellbeing
Study: NCT04183270

Intervention type: OTHER
Intervention: Questionnaires
Description: The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.

Intervention type: OTHER
Intervention: Questionnaires
Description: The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
Study: NCT03651050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith Based Outreach (FBO)
Description: Faith base outreach groups will be trained in P-MHDT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-health-workers (CHW)
Description: COmmon health workers will be trained in P-MHDT
Study: NCT04064151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Guide
Description: 12-week long health promotion Smartphone application
Study: NCT01764087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 and Paclitaxel
Description: A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
Study: NCT00286845

Intervention type: DRUG
Intervention: Standard Chemotherapy
Description: physician determined
Study: NCT00627380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga lifestyle intervention
Description: Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
Study: NCT01774513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procore-Needle
Study: NCT02899494

Intervention type: OTHER
Group type: OTHER
Intervention: Antenatal classes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and psychic preparation
Study: NCT04241094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loved one assisted treatment
Description: The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
Study: NCT01610310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
Study: NCT02062047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMSRP
Description: FMSRP in a maximum of 24 hours.
Study: NCT01610310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Autoinjector
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a) Autoinjector
Description: 125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
Study: NCT02388802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte retrieval and freezing
Description: 10 Patients will undergo oocyte retrieval and freezing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased Donor Allograft Excision
Description: Appropriately matched uterine transplant allografts will be excised from deceased donors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplantation
Description: Following egg freezing the patients will undergo uterine transplant from deceased donors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-vitro fertilisation
Description: 12 months after successful transplantation,the patients will undergo IVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caesarean Section
Description: Following successful conception and antenatal period, the babies will be born by Caesarean Section
Study: NCT02432105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study: NCT04232683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4Mg Capsule
Description: Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo pill given preoperatively
Study: NCT01256567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
Study: NCT03275025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 low dose
Description: A low dose of YRA-1909; daily oral intake for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 mid dose
Description: A mid dose of YRA-1909; daily oral intake for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YRA-1909 high dose
Description: A high dose of YRA-1909; daily oral intake for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study: NCT03651648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSITACT System
Description: the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SENSITACT System
Description: the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
Study: NCT03133026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single operator cholangioscopy, Endoscopic biliary RFA
Description: Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single operator cholangioscopy, Endoscopic biliary RFA
Description: Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
Study: NCT01763710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel 80 mg/m2
Description: Paclitaxel 80 mg/m2 days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
Description: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
Description: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 days 1 and 15
Description: Nab-paclitaxel 150 mg/m2 days 1 and 15
Study: NCT00316173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARBOPLATIN
Description: HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
Study: NCT04127838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Occupational Therapy
Description: Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
Study: NCT00243880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
Study: NCT02568748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Trans-arterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Trans-arterial chemoembolization
Study: NCT00816881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flutter mucus clearance device
Description: five minutes every session, four sessions per day
Study: NCT03084926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0274
Description: Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
Study: NCT01394900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CNU Intervention
Description: Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WP Intervention
Description: Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
Study: NCT01760096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole+cyclosporin A+Glucocorticoids
Description: Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A+Glucocorticoids
Description: cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Glucocorticoids0.25mg/kg every day(prednisone)
Study: NCT03406728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDSAFEX
Description: PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY
Description: WorldViz Oculus Rift Move package (headset and software).
Study: NCT02618616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-3893787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo